Cell Models & Assay Development
Our R&D teams are specialized in developing cutting-edge cell models and assays. Our expertise lies in creating innovative cell-based systems that mimic biological processes, enabling improved in vivo translation and reliable data generation.
Backed by a multidisciplinary team of scientists and state-of-the-art facilities, we are committed to pushing the boundaries of cell models and assay development to be able to accelerate the development of drug candidates.
For further information, please contact CSO Christian Clausen by email or phone.
CNS Modelling & Assay Development
The value of using human neuronal cell models for drug discovery in the CNS field is now evident. By utilizing technologies like CRISPR engineering, multicellular models and continuously optimized neuronal differentiation protocols towards neural cellular subtypes, these models have the potential to revolutionize the preclinical development in the CNS field. For more than a decade, Bioneer has developed cell models in the CNS field that address the need for improved in vivo translation.
Our R&D program is focusing on the development of neuronal models and image-based screening assays (Image Xpress platform), e.g. aggregation models mimicking pathological hallmarks of Alzheimer’s disease and Parkinson’s Disease as well as advanced co-culture models combining e.g. neurons and astrocytes and human blood-brain-barrier (BBB) models.
The importance of neuroinflammation across neurodegenerative diseases is becoming increasingly clear. More and more underlying molecular mechanisms have been revealed, which provides compelling evidence for developing therapeutic strategies that regulate neuroinflammation to prevent CNS pathologies. We address this by developing a catalogue of microglia cell models and assays that capture relevant neuroinflammatory read-outs.
Our automated Image Xpress high content imaging platform makes it possible to develop highly advanced multiparameter screening assays coupled to our CNS cell models.
Functional read-outs will be important for some CNS drug development and we therefore tailor our development of new CNS cell models to be able to integrate electrophysiology (MEA technology) read-outs.
During the program we exploit the use of artificial intelligence to develop prediction tools based on various biological and functional data generated from the CNS cell models.
Our CNS in vitro modelling program will enable us to continue and expand our role as integrated R&D partner to CNS focused companies worldwide.
Our R&D program is focusing on the development of neuronal models and image-based screening assays (Image Xpress platform), e.g. aggregation models mimicking pathological hallmarks of Alzheimer’s disease and Parkinson’s Disease as well as advanced co-culture models combining e.g. neurons and astrocytes and human blood-brain-barrier (BBB) models.
The importance of neuroinflammation across neurodegenerative diseases is becoming increasingly clear. More and more underlying molecular mechanisms have been revealed, which provides compelling evidence for developing therapeutic strategies that regulate neuroinflammation to prevent CNS pathologies. We address this by developing a catalogue of microglia cell models and assays that capture relevant neuroinflammatory read-outs.
Our automated Image Xpress high content imaging platform makes it possible to develop highly advanced multiparameter screening assays coupled to our CNS cell models.
Functional read-outs will be important for some CNS drug development and we therefore tailor our development of new CNS cell models to be able to integrate electrophysiology (MEA technology) read-outs.
During the program we exploit the use of artificial intelligence to develop prediction tools based on various biological and functional data generated from the CNS cell models.
Our CNS in vitro modelling program will enable us to continue and expand our role as integrated R&D partner to CNS focused companies worldwide.
Cancer Modelling & Assays
The use of 3D cell models during early development of cancer drug candidates is now recognized as a valuable strategy and has a tremendous potential for elucidating new disease determinants and identifying new drug targets for cancer treatment.
At Bioneer, we combine our deep expertise in biomarker imaging, cancer cell biology and immunology throughout this R&D program to develop multicellular 3D cancer models for evaluation of cancer drug candidates as well as immune-oncology drug candidates. By working in cross-disciplinary teams we develop 3D cancer cell models mimicking the in vivo tumor microenvironment to the extent possible. Additionally, we develop techniques allowing e.g. infiltration of various immune cells into such models.
During the program we will explore the use of artificial intelligence to develop prediction tools based on various biological data generated from the 3D cancer cell models.
Our ultimate goal is to expand our solutions in the cancer field by developing a catalogue of the best cancer cell models, especially within immuno-oncology.
At Bioneer, we combine our deep expertise in biomarker imaging, cancer cell biology and immunology throughout this R&D program to develop multicellular 3D cancer models for evaluation of cancer drug candidates as well as immune-oncology drug candidates. By working in cross-disciplinary teams we develop 3D cancer cell models mimicking the in vivo tumor microenvironment to the extent possible. Additionally, we develop techniques allowing e.g. infiltration of various immune cells into such models.
During the program we will explore the use of artificial intelligence to develop prediction tools based on various biological data generated from the 3D cancer cell models.
Our ultimate goal is to expand our solutions in the cancer field by developing a catalogue of the best cancer cell models, especially within immuno-oncology.
Gene Editing & Immune models
Being able to modify the genome in human immune cells opens up a wide range of possibilities to develop novel in vitro immune models for both Mode of Actions studies and safety across several diseases, including cancer.
The R&D program involves our experts in both gene editing and immunology, where our gene editing technologies are used to develop processes that can modify T-cells, NK cells and macrophages.
In addition, protocols for differentiation of human induced pluripotent stem cells to a variety of immune cells are being developed, making it possible to perform gene editing on the stem cell stage followed by immune cell directed differentiation.
Our ambition is to develop novel human immune and cancer models providing the best solutions to companies across modalities including cell therapies, therapeutic antibodies and peptides.
The R&D program involves our experts in both gene editing and immunology, where our gene editing technologies are used to develop processes that can modify T-cells, NK cells and macrophages.
In addition, protocols for differentiation of human induced pluripotent stem cells to a variety of immune cells are being developed, making it possible to perform gene editing on the stem cell stage followed by immune cell directed differentiation.
Our ambition is to develop novel human immune and cancer models providing the best solutions to companies across modalities including cell therapies, therapeutic antibodies and peptides.
For further information
please contact:
